1+ day, 6+ hour ago   (401+ words) The Clinical Trial Vanguard Tam-Peli meets primary endpoint for relapsed small-cell lung cancer in phase III trial Topotecan has been the default second-line chemotherapy for relapsed small-cell lung cancer for decades, and its survival benefit in that setting is modest…...

1+ day, 6+ hour ago   (861+ words) The Clinical Trial Vanguard Mitapivat Just Rewrote the Treatment Floor for Transfusion-Dependent Thalassaemia, Here’s What the ENERGIZE-T Data Actually Mean Picture the patient record that has defined thalassaemia care for decades: a transfusion schedule, printed or scrolling across a clinic…...

1+ day, 6+ hour ago   (362+ words) clinicaltrialvanguard.com Iza-bren 2.5 mg/kg dose advances to Phase 3 in EGFR-mutated NSCLC Three dose levels entered a randomized expansion cohort; only one came out with a Phase 3 ticket. SystImmune and Bristol Myers Squibb will present at WCLC in Seoul on…...

4+ day, 6+ hour ago   (344+ words) The Clinical Trial Vanguard Tyra Selects 60mg Dose of Dabogratinib in NMIBC Phase 2 Study Sixty milligrams once daily: that is the dose Tyra Biosciences selected from SURF302 after the Phase 2 study returned its first results on September 9, and the choice carries real…...

4+ day, 6+ hour ago   (422+ words) The Clinical Trial Vanguard Insilico Medicine Begins Phase III Trial of AI-Discovered Drug Rentosertib for IPF Rentosertib just cleared a threshold no AI-discovered drug has reached before: 320 patients, 47 sites, 52 weeks of treatment in a randomized, double-blind, placebo-controlled Phase III. Insilico Medicine…...

5+ day, 6+ hour ago   (463+ words) clinicaltrialvanguard.com Advarra Releases IRB Reportable Events Checklist to Reduce Over-Reporting Most research teams think the hard part of IRB compliance is catching every event. The harder part, the one that actually generates audit findings, is knowing which events to…...

5+ day, 6+ hour ago   (322+ words) The Clinical Trial Vanguard BridgeBio Shifts BBO-8520 Focus to KRAS Combinations in Second-Line NSCLC A 63% objective response rate from a Phase 1 monotherapy arm is an unusual number to anchor a strategic pivot on, but that is what BridgeBio Oncology Therapeutics…...

5+ day, 6+ hour ago   (368+ words) The Clinical Trial Vanguard Mosliciguat Advances to Phase 3 PHrontier Trial After PHocus Study Shows 20% PVR Reduction Mosliciguat cut pulmonary vascular resistance by 20 percent in Roivant’s Phase 2 PHocus trial, a result that now sends the once-daily inhaled drug directly into a…...

6+ day, 6+ hour ago   (459+ words) clinicaltrialvanguard.com Clinical trial sites advised to build data infrastructure before deploying AI tools About three-quarters of clinical trial sites now use eSource in active studies, according to a 2024 RealTime Reports survey, yet the panel that CRIO and Clinical Leader…...

1+ week, 6+ hour ago   (442+ words) The Clinical Trial Vanguard Clover’s RSV-hMPV Vaccine Shows Antibody Rises in Phase 2 Trial More than half of American adults 75 and older have already received one of the approved RSV vaccines, which creates an awkward problem for any late-entrant vaccine: the…...